Home LiteratureArticle Details
PMID: 22671927 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.

Current cancer drug targets ·Vol. 12 ·No. 7 ·2012-09-00 ·Pages 814-22

Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P

Abstract

Mouse models of multiple myeloma (MM) are basic tools for translational research and play a fundamental role in the development of new therapeutics against plasma cell malignancies. All available models, including transplantable murine tumors in syngenic mice, xenografts of established human cell lines in immunocompromised mice and transgenic models that mirror specific steps of MM pathogenesis, have demonstrated some weaknesses in predicting clinical results, particularly for new drugs targeting the human bone marrow microenvironment (huBMM). The recent interest to models recapitulating the in vivo growth of primary MM cells in a human (SCID-hu) or humanized (SCID-synth-hu) host recipient has provided powerful platforms for the investigation of new compounds targeting MM and/or its huBMM. Here, we review and discuss strengths and weaknesses of the key in vivo models that are currently utilized in the MM preclinical investigation.

MeSH Terms
Animals Antineoplastic Agents/pharmacology,therapeutic use Disease Models, Animal Drug Evaluation, Preclinical Humans Mice Multiple Myeloma/drug therapy
Chemicals
Antineoplastic Agents
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Tassone P
Medical Oncology, Magna Græcia University, Viale Europa, Campus Salvatore Venuta, 88100 Catanzaro, Italy. tassone@unicz.it
Neri P
Burger R
Di Martino M T
Leone E
Amodio N
Caraglia M
Tagliaferri P
References (87)
87 references, click to expand
  1. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.
    Curr Pharm Des. 2007;13(5):487-96 PMID: 17348845
  2. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.
    Cancer Cell. 2008 Feb;13(2):167-80 PMID: 18242516
  3. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy.
    Eur J Cancer. 2006 Jul;42(11):1640-52 PMID: 16797969
  4. Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse.
    Blood. 1994 Sep 1;84(5):1393-8 PMID: 7520766
  5. Animal models: Towards a myeloma mouse.
    Nature. 2011 Dec 14;480(7377):S38-9 PMID: 22169799
  6. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Clin Cancer Res. 2002 Oct;8(10):3198-204 PMID: 12374689
  7. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
    Clin Cancer Res. 2006 Nov 15;12(22):6603-10 PMID: 17121878
  8. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
    Blood. 2012 Jul 12;120(2):376-85 PMID: 22451422
  9. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
    Clin Cancer Res. 2008 Apr 1;14(7):2154-60 PMID: 18381957
  10. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse.
    Br J Cancer. 1997;76(4):451-60 PMID: 9275021
  11. The 5TMM series: a useful in vivo mouse model of human multiple myeloma.
    Hematol J. 2000;1(5):351-6 PMID: 11920212
  12. Pathogenesis of myeloma.
    Annu Rev Pathol. 2011;6:249-74 PMID: 21261519
  13. IL-6 transgenic mouse model for extraosseous plasmacytoma.
    Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1509-14 PMID: 11805288
  14. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Clin Exp Metastasis. 2006;23(5-6):291-300 PMID: 17086356
  15. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse.
    Immunol Today. 1990 Jul;11(7):234-6 PMID: 2201308
  16. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1.
    Nat Immunol. 2003 Apr;4(4):321-9 PMID: 12612580
  17. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
    Blood. 2007 Feb 1;109(3):1220-7 PMID: 17032924
  18. Bone marrow microenvironment and the identification of new targets for myeloma therapy.
    Leukemia. 2009 Jan;23(1):10-24 PMID: 18843284
  19. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62 PMID: 17379101
  20. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.
    Blood. 1997 Sep 15;90(6):2437-44 PMID: 9310495
  21. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
    Int J Cancer. 2007 Apr 15;120(8):1657-63 PMID: 17230522
  22. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma.
    Hematol J. 2001;2(1):42-53 PMID: 11920233
  23. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Clin Cancer Res. 2005 Jun 1;11(11):4251-8 PMID: 15930364
  24. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
    Oncogene. 2003 Jan 30;22(4):517-27 PMID: 12555065
  25. Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.
    Br J Cancer. 2011 Nov 22;105(11):1708-18 PMID: 22045188
  26. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
    Eur J Cancer. 2004 Apr;40(6):858-80 PMID: 15120042
  27. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):621-9 PMID: 17255285
  28. Idiopathic paraproteinaemia. I. Studies in an animal model--the ageing C57BL/KaLwRij mouse.
    Clin Exp Immunol. 1978 Sep;33(3):395-402 PMID: 367647
  29. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
    Blood. 2005 Aug 15;106(4):1341-5 PMID: 15886318
  30. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
    Clin Cancer Res. 2012 Apr 1;18(7):1888-900 PMID: 22351691
  31. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
    Leukemia. 2007 Dec;21(12):2519-26 PMID: 17882285
  32. A clinically relevant SCID-hu in vivo model of human multiple myeloma.
    Blood. 2005 Jul 15;106(2):713-6 PMID: 15817674
  33. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
    Leukemia. 2008 Jul;22(7):1410-8 PMID: 18449204
  34. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    J Bone Miner Res. 2003 Mar;18(3):482-92 PMID: 12619933
  35. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies.
    Curr Pharm Des. 2008;14(21):2023-39 PMID: 18691113
  36. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
    Cancer Res. 2002 Apr 15;62(8):2300-5 PMID: 11956087
  37. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    Cancer Res. 2002 Sep 1;62(17):4996-5000 PMID: 12208752
  38. Purging of myeloma cells using all-trans retinoic acid in a mouse model.
    Exp Hematol. 2001 Mar;29(3):315-21 PMID: 11274759
  39. Antimyeloma efficacy of thalidomide in the SCID-hu model.
    Blood. 2002 Dec 1;100(12):4162-8 PMID: 12393672
  40. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Clin Cancer Res. 2006 Oct 1;12(19):5887-94 PMID: 17020997
  41. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Neoplasia. 2010 Jan;12(1):28-38 PMID: 20072651
  42. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
    Clin Cancer Res. 2007 Oct 1;13(19):5903-9 PMID: 17908986
  43. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.
    Clin Exp Metastasis. 2002;19(1):87-90 PMID: 11918087
  44. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
    J Clin Invest. 2004 Jun;113(12):1763-73 PMID: 15199411
  45. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
    Leukemia. 2011 Apr;25(4):707-11 PMID: 21233838
  46. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
    Eur J Immunol. 1992 Aug;22(8):1989-93 PMID: 1639101
  47. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice.
    Blood. 1993 Oct 15;82(8):2526-36 PMID: 8104540
  48. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
    Blood. 2008 Aug 15;112(4):1346-56 PMID: 18524994
  49. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone.
    Cell Death Differ. 2000 Mar;7(3):327-8 PMID: 10866493
  50. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice.
    J Bone Miner Res. 1999 Feb;14(2):256-63 PMID: 9933480
  51. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.
    Science. 1988 Sep 23;241(4873):1632-9 PMID: 2971269
  52. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
    Blood. 2009 Jul 9;114(2):371-9 PMID: 19417213
  53. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
    Blood. 2006 May 15;107(10):4053-62 PMID: 16418332
  54. A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
    Br J Cancer. 2006 Oct 23;95(8):961-5 PMID: 17047643
  55. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
    Cancer Res. 2007 May 1;67(9):4069-78 PMID: 17483317
  56. Preclinical analysis of cytokine therapy in the SCID-hu mouse.
    Blood. 1993 Mar 15;81(6):1479-88 PMID: 7680919
  57. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
    Leukemia. 2009 Oct;23(10):1894-903 PMID: 19494837
  58. Modelling haematopoietic malignancies in the mouse and therapeutical implications.
    Oncogene. 2002 May 13;21(21):3445-58 PMID: 12032781
  59. The development of a model for the homing of multiple myeloma cells to human bone marrow.
    Blood. 1997 Jul 15;90(2):754-65 PMID: 9226176
  60. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Br J Haematol. 2008 Nov;143(4):520-31 PMID: 18986388
  61. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.
    Curr Cancer Drug Targets. 2009 Nov;9(7):854-70 PMID: 20025573
  62. Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.
    Mol Cancer Ther. 2002 Dec;1(14):1361-5 PMID: 12516971
  63. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
    Clin Cancer Res. 2009 Dec 1;15(23):7144-52 PMID: 19934301
  64. Multiple myeloma.
    Lancet. 2009 Jul 25;374(9686):324-39 PMID: 19541364
  65. A murine model of human myeloma bone disease.
    Bone. 1997 Jun;20(6):515-20 PMID: 9177864
  66. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.
    Blood. 2006 Jan 15;107(2):655-60 PMID: 16046527
  67. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.
    Br J Cancer. 2008 Jun 17;98(12):1966-74 PMID: 18521088
  68. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.
    Cancer Cell. 2007 Apr;11(4):349-60 PMID: 17418411
  69. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
    Mol Cancer Ther. 2009 Jan;8(1):26-35 PMID: 19139110
  70. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
    Br J Haematol. 2006 Jul;134(1):37-44 PMID: 16803565
  71. Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice.
    Cancer Sci. 2004 Jul;95(7):564-8 PMID: 15245591
  72. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
    Cancer Res. 2011 Jan 15;71(2):339-48 PMID: 21224354
  73. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
    Blood. 2000 Feb 1;95(3):1056-65 PMID: 10648422
  74. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
    Blood. 1998 Oct 15;92(8):2908-13 PMID: 9763577
  75. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
    Cancer Res. 2003 Oct 15;63(20):6689-96 PMID: 14583463
  76. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
    Blood. 2005 Jun 1;105(11):4470-6 PMID: 15705788
  77. Long-term engraftment of fresh human myeloma cells in SCID mice.
    Blood. 1992 Dec 1;80(11):2843-50 PMID: 1450409
  78. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
    Int J Oncol. 2006 Jun;28(6):1409-17 PMID: 16685443
  79. Multiple myeloma.
    N Engl J Med. 2011 Mar 17;364(11):1046-60 PMID: 21410373
  80. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
    Leukemia. 2004 Nov;18(11):1891-7 PMID: 15385929
  81. Emerging therapies for multiple myeloma.
    Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127 PMID: 19249983
  82. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
    Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83 PMID: 17164332
  83. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
    Int J Oncol. 2002 Oct;21(4):867-73 PMID: 12239628
  84. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Cancer Res. 2007 Jan 1;67(1):202-8 PMID: 17210700
  85. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
    Blood. 2004 Dec 1;104(12):3688-96 PMID: 15292058
  86. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
    Cancer Res. 2004 Jul 1;64(13):4629-36 PMID: 15231675
  87. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?
    Eur J Cancer. 2006 Jul;42(11):1530-8 PMID: 16820292
Article Info
Journal
Current cancer drug targets
Abbr.
Curr Cancer Drug Targets
ISSN
1873-5576
DOI
10.2174/156800912802429292
Email
tassone@unicz.it
Published
2012-09-00
Pages
814-22
Language
English
Region
Netherlands
NLM ID
101094211
PMCID
PMC3587184
Subset
IM
External Links
PubMed source DOI: 10.2174/156800912802429292 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2